EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine
2022-10-31
疫苗
PROVIDENCE, R.I., Oct. 31, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic Preparedness Innovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2. EpiVax will be carrying out the vaccine epitope selection portion of the collaboration using their comprehensive in silico vaccine design toolkit "
iVAX".
Continue Reading
This program is funded under CEPI's 2021 call for proposals to accelerate the development of broadly protective coronavirus vaccines, which will provide up to US$200 million for such projects. Intravacc was awarded $4.8 million to advance their subunit vaccine candidate "Avacc 101", which is designed for intranasal delivery to provide protective immunity for multiple betacoronaviruses including SARS-CoV-1, SARS-CoV-2, and MERS-CoV. Avacc 101 uses Intravacc's Outer Membrane Vesicle (OMV) technology to deliver vaccine payloads for an effective immune response.
Tweet this
As a subgrantee on the project, EpiVax will identify cross-reactive beta-coronavirus T cell epitopes for broad coverage of COVID-19, MERS and SARS Class 1 and Class 2 HLA-restricted epitopes, using the iVAX in silico vaccine design toolkit. In addition to vaccine epitope selection, EpiVax will also develop multiple designs, and will validate these in silico constructs in vivo with HLA-transgenic mice.
According to EpiVax CEO/CSO Dr. Annie De Groot, "We sincerely appreciate the opportunity to apply our advanced vaccine design tools to a problem of global significance.".
About EpiVax:
EpiVax is a biotechnology company with expertise in T cell epitope prediction, immune modulation, and rapid vaccine design. EpiVax's immunogenicity screening toolkits for therapeutics and vaccines, ISPRI and iVAX, are employed in advancing the research of a global roster of companies. For more information, visit www.epivax.com.
About Intravacc:
Intravacc is a leading global contract development and manufacturing organization (CDMO) of innovative vaccines against infectious diseases. Intravacc has transferred its technology related to polio vaccines, measles vaccines, DPT vaccines, Hib vaccines and influenza vaccines around the world. Intravacc offers a wide range of expertise to develop vaccine from concept to Phase I/II clinical studies for academic, industry and philanthropic partners. For more information, visit www.intravacc.nl.
Press Contact:
Katie Porter, Associate Director, Business Development & Marketing
[email protected]
Source: EpiVax, Inc.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。